ClinicalTrials.gg
Active, not recruitingNCT06139055Updated Feb 15, 2024

A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese Participants

A Phase 1 interventional study of GSBR-1290 (Capsule/Tablet) and GSBR-1290 in Healthy Volunteers, sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics (part of Structure Therapeutics) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to compare the safety, tolerability, pharmacokinetic (PK), and comparative bioavailability of repeated administration of GSBR-1290 in healthy overweight/obese participants.

Read the detailed description

This is a 2-part study in which Part 1 will compare the PK of GSBR-1290, administered as tablet and capsule, using a 2-period, 2-sequence, crossover design in approximately 16 healthy overweight/obese participants. Part 2 will evaluate multiple-ascending doses of GSBR-1290 tablet in 3 cohorts, using 3 different titration regimens. Secondly in Part 2, the study will evaluate the comparative bioavailability of GSBR-1290 tablet versus capsule at a potentially clinically efficacious dose at steady state in Cohort 3.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics is the lead sponsor of 10 studies on the registry; 3 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provided evidence of a signed before any study-related activities are initiated and be willing to comply with all study procedures.
  2. Healthy overweight or obese adult men and women.
  3. Age greater then or equal to (>=)18 and less than or equal to (\<=) 75 years.
  4. (BMI) >=27.0 kilogram per square meter (kg/m\^2).

Exclusion criteria

Exclusion Criteria:

  1. History or presence of cardiovascular, pulmonary, hepatic, renal, hematological, gastrointestinal, endocrine, immunologic, dermatologic, or neurological disease.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
70 participants (actual)

Study arms

  • Experimental
    Part 1 (Sequence 1: Capsule to Tablet): GSBR-1290 Capsule/GSBR-1290 Tablet

    Participants will receive a single dose of GSBR-1290 oral capsule formulation on Day 1 in Treatment Period 1 followed by GSBR-1290 oral tablet formulation on Day 8 (Day 1 of Treatment Period 2).

    Drug: GSBR-1290 (Capsule/Tablet)

  • Experimental
    Part 1(Sequence 2: Tablet to Capsule): GSBR-1290 Tablet/GSBR-1290 Capsule

    Participants will receive a single dose of GSBR-1290 oral tablet formulation on Day 1 in Treatment Period 1 followed by GSBR-1290 oral capsule formulation on Day 8 (Day 1 of Treatment Period 2).

    Drug: GSBR-1290 (Capsule/Tablet)

  • Experimental
    Part 2 (Cohort 1): GSBR-1290/Placebo Tablet

    Participants will receive GSBR-1290 or matching-placebo oral tablets once daily for a total of 12 weeks.

    Drug: GSBR-1290 · Drug: Placebo

  • Experimental
    Part 2 (Cohort 2): GSBR-1290/Placebo Tablet

    Participants will receive GSBR-1290 or matching-placebo oral tablets once daily for a total of 12 weeks.

    Drug: GSBR-1290 · Drug: Placebo

  • Experimental
    Part 2 (Cohort 3): GSBR-1290/Placebo Tablet and GSBR-1290/Placebo Capsule

    Participants will receive GSBR-1290 or matching-placebo oral tablets once daily for a total of 12 weeks. In the last 4 weeks, participants will be further randomized to GSBR-1290 capsules or tablets or matching-placebo at Week 9 to 10 followed by alternate (capsule or tablet) formulation of either GSBR-1290 or placebo at Week 11 to 12.

    Drug: GSBR-1290 (Capsule/Tablet) · Drug: Placebo (Capsule/Tablet)

Interventions

  • DrugGSBR-1290 (Capsule/Tablet)

    Drug page: Aleniglipron

    Participants will receive GSBR-1290 oral capsules or tablets.

  • Participants will receive GSBR-1290 oral tablets.

  • DrugPlacebo

    Participants will receive matching-placebo oral tablets.

  • DrugPlacebo (Capsule/Tablet)

    Participants will receive matching-placebo oral capsules or tablets.

06

What researchers measure

Primary outcomes

  1. Part 1: Analysis of Maximum Observed Plasma Concentration (Cmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate Pharmacokinetic (PK) Parameters

    Time frame: From start of study drug up to Day 10

  2. Part 1: Analysis of Time to Maximum Observed Plasma Concentration (Tmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters

    Time frame: From start of study drug up to Day 10

  3. Part 1: Analysis of Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Concentration (AUC0-t) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters

    Time frame: From start of study drug up to Day 10

  4. Part 1: Analysis of Area Under the Plasma Concentration-time Curve From 0 to infinity (AUC0-inf) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters

    Time frame: From start of study drug up to Day 10

  5. Part 1: Analysis of Apparent Terminal Elimination Half-life (t1/2) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters

    Time frame: From start of study drug up to Day 10

  6. Part 1: Analysis of Total Apparent Body Clearance (CL/F) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters

    Time frame: From start of study drug up to Day 10

  7. Part 1: Analysis of Apparent Volume of Distribution (Vz/F) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters

    Time frame: From start of study drug up to Day 10

  8. Part 2: Number of Participants With Adverse Events (AEs) and Serious AEs

    Time frame: From start of study drug up to End of study (EOS) in Part 2 (up to Day 98)

  9. Part 2: Number of Participants With Severity of AEs

    Time frame: From start of study drug up to EOS in Part 2 (up to Day 98)

  10. Part 2: Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Time frame: From start of study drug up to EOS in Part 2 (up to Day 98)

  11. Part 2: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters

    Time frame: From start of study drug up to EOS in Part 2 (up to Day 98)

  12. Part 2: Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

    Time frame: From start of study drug up to EOS in Part 2 (up to Day 98)

Secondary outcomes

  1. Part 1: Number of Participants With Adverse Events (AEs) and Serious AEs

    Time frame: From start of study drug up to EOS in Part 1 (Day 17)

  2. Part 1: Number of Participants Based on Severity of AEs

    Time frame: From start of study drug up to EOS in Part 1 (Day 17)

  3. Part 1: Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Time frame: Baseline up to EOS in Part 1 (Day 17)

  4. Part 1: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Parameters

    Time frame: Baseline up to EOS in Part 1 (Day 17)

  5. Part 1: Number of Participants With Clinically Significant Change From Baseline in Laboratory Parameters

    Time frame: Baseline up to EOS in Part 1 (Day 17)

  6. Part 2: Analysis of Maximum Observed Plasma Concentration (Cmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate Pharmacokinetic (PK) Parameters

    Time frame: From start of study drug up to Day 84

  7. Part 2: Analysis of Time to Maximum Observed Plasma Concentration (Tmax) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters

    Time frame: From start of study drug up to Day 84

  8. Part 2: Analysis of Area Under the Plasma Concentration-time Curve From Time Zero to the End of the Dosing Interval (24 hours) at Steady State (AUC0-tau) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters

    Time frame: From start of study drug up to Day 84

  9. Part 2: Analysis of Plasma Trough Concentrations for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters

    Time frame: From start of study drug up to Day 84

  10. Part 2: Analysis of Apparent Terminal Elimination Half-life (t1/2) for GSBR-1290 at Specified Timepoints Pre-dose and Post-dose to Calculate PK Parameters

    Time frame: From start of study drug up to Day 84

07

Study locations

3 sites
  • ERG Clinical (Clinical Pharmacology of Miami - CPMI)
    Miami, Florida 33014, United States
  • Syneos Miami Site
    Miami, Florida 33131, United States
  • Parexel Baltimore Early Phase Clinical Unit
    Baltimore, Maryland 21225, United States
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request

Supporting information: Study protocol

Time frame: Data sharing requests will be considered beginning 36 months after the study publication (manuscript accepted for publication) and either 1) the product have been granted marketing authorization in at least two regulatory jurisdictions, or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Researchers will submit a request containing the research objectives, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). Structure Therapeutics does not grant external requests for individual de-identified patient data for the following purposes: re-evaluating safety and efficacy end points already addressed in the product labelling, assessing safety or efficacy for an indication in current development Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a panel of external advisors. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Mar 2024, 5 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2023
First posted
Nov 18, 2023
StartActual
Oct 2, 2023
Primary completionEst.
Mar 2024
CompletionEst.
Mar 2024
Last update
Feb 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06139055
Responsible party
Sponsor
First posted
Nov 18, 2023
Start date
Oct 2, 2023
Primary completion
Mar 2024 (estimated)
Completion
Mar 2024 (estimated)
Last update
Feb 15, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aleniglipron

Start the discussion